Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 11 art units • 16 examiners • 0 of 18 (0%) have an AI response strategy ready • 24 patents granted in the last 365 days
Iovance Biotherapeutics Inc. currently manages 19 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 18 distinct examiners and 11 distinct art units. This indicates a broad prosecution front where nearly every pending action is being handled by a different examiner. With 11 distinct art units involved, the company's biotechnology applications are subject to a wide range of technical reviews and examiner-specific practices across the USPTO.
CHASE, CAROL ANN is the busiest examiner, responsible for 2 of the pending office actions. The remaining actions are handled by the distinct examiners. This distribution requires the company to adapt its legal strategies to the specific preferences of many different individuals while maintaining a cohesive approach across the 11 distinct art units represented in the portfolio.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 3 (17%) |
| Double-patenting + other | 8 (44%) |
| Multi-statute (no §101) | 5 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHASE, CAROL ANN | 2 | 41.9% | +84.9% |
| JUEDES, AMY E | 2 | 44.7% | +41.9% |
| TOWNSEND, GUY K | 1 | 74.4% | +25.1% |
| DRISCOLL, MAUREEN VARINA | 1 | 64.9% | +41.8% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
| JOHNSON, KARA D | 1 | 69.3% | +25.1% |
| BARRON, SEAN C | 1 | 52.7% | +30.4% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| WEN, SHARON X | 1 | 56.8% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997731 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | ZHU, JIANJIAN | 29d |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | STONEBRAKER, ALYSSA RAE | 55d |
| 18661510 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | JOHNSON, KARA D | — |
| 18580107 | METHOD FOR CRYOPRESERVATION OF SOLID TUMOR FRAGMENTS | BARRON, SEAN C | — |
| 18474824 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | BRISTOL, LYNN ANNE | — |
| 18249380 | CELL CULTURE SYSTEM AND METHODS OF USING THE SAME | HURST, JONATHAN M | — |
| 17415175 | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof | JUEDES, AMY E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262843 | ADJUVANT THERAPY FOR CANCER | WEN, SHARON X | 20d |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | STONEBRAKER, ALYSSA RAE | 55d |
| 18878574 | Packaging For Biological Samples | TOWNSEND, GUY K | — |
| 18886988 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | DRISCOLL, MAUREEN VARINA | — |
| 18661510 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | JOHNSON, KARA D | — |
| 18609772 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | CHASE, CAROL ANN | — |
| 18429006 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS | JUEDES, AMY E | — |
| 18580107 | METHOD FOR CRYOPRESERVATION OF SOLID TUMOR FRAGMENTS | BARRON, SEAN C | — |
| Art Unit | Apps |
|---|---|
| 1644 | 3 |
| 1646 | 3 |
| 1642 | 2 |
| 1641 | 2 |
| 1631 | 2 |
| 3733 | 1 |
| 1632 | 1 |
| 1653 | 1 |
| 1643 | 1 |
| 1799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18878574 | Packaging For Biological Samples | TOWNSEND, GUY K | 3733 | §103 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18886988 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | DRISCOLL, MAUREEN VARINA | 1644 | §103§112DP | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | STONEBRAKER, ALYSSA RAE | 1642 | §103§112Other | Final Rejection | 55d | Pending | May 23, 2024 |
| 18661510 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | JOHNSON, KARA D | 1632 | §101§102§103§112DP | Non-Final OA | — | Pending | May 10, 2024 |
| 18609772 | CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS | CHASE, CAROL ANN | 1646 | §102§103DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18429006 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS | JUEDES, AMY E | 1644 | §103Other | Final Rejection | — | Pending | Jan 31, 2024 |
| 18580107 | METHOD FOR CRYOPRESERVATION OF SOLID TUMOR FRAGMENTS | BARRON, SEAN C | 1653 | §102§103 | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18560898 | PD-1 GENE-EDITED TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | CHASE, CAROL ANN | 1646 | §102§103DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18474824 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | BRISTOL, LYNN ANNE | 1643 | §101§103§112Other | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18551138 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | HUYNH, PHUONG N | 1641 | §103§112DP | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18262843 | ADJUVANT THERAPY FOR CANCER | WEN, SHARON X | 1641 | §103DP | Final Rejection | 20d | Pending | Jul 25, 2023 |
| 18249380 | CELL CULTURE SYSTEM AND METHODS OF USING THE SAME | HURST, JONATHAN M | 1799 | §102§103 | Non-Final OA | — | Pending | Apr 17, 2023 |
| 18247878 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | AEDER, SEAN E | 1642 | §103Other | Non-Final OA | — | Pending | Apr 04, 2023 |
| 18182676 | Expansion Of Peripheral Blood Lymphocytes (PBLS) From Peripheral Blood | SANG, HONG | 1646 | §103§112DP | Final Rejection | — | Pending | Mar 13, 2023 |
| 17997731 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | ZHU, JIANJIAN | 1631 | §102§103§112Other | Non-Final OA | 29d | Pending | Nov 01, 2022 |
| 17812146 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEROF | MIANO, JOSEPH PAUL | 1631 | §103DP | Final Rejection | — | Pending | Jul 12, 2022 |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | KELLY, ROBERT M | 1638 | §112DP | Non-Final OA | 23d | Pending | May 31, 2022 |
| 17415175 | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof | JUEDES, AMY E | 1644 | §103§112Other | Final Rejection | — | Pending | Jun 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIovance Biotherapeutics Inc. has 18 pending office actions as of October 2026, spread across 11 art units and 16 examiners.
Carol Ann Chase has the most, with 2 of Iovance Biotherapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
